Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
Upon approval, Rocket has been awarded a priority review voucher, which currently fetch around $200m on the secondary market.
Cytiva Navigating cell therapy WP 4
Nonprofit models support strategic boldness to develop gene therapies for rare diseases
Gene editing takes centre stage in FDA’s new rare disease approval pathway
Gilead acquires CAR-T specialist Arcellx for $7.8bn
J&J to build $1bn US CGT manufacturing site in Pennsylvania
REGENXBIO receives FDA response for RGX-121 application
Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout
Sensorion announces $71.9m reserved offering to expand gene therapy pipeline
